Investor Class Action Filed Against Acadia Healthcare Company, Inc. for Securities Fraud Violations

Notice is hereby given that a class action lawsuit has been filed on behalf of those who purchased or otherwise acquired Acadia Healthcare Company, Inc. (“Acadia”) (Nasdaq: ACHC) securities between February 23, 2017 and October 24, 2017, inclusive (the “Class Period”).

Acadia investors may receive additional information about the case by clicking the link "Submit Your Information" above.

According to the complaint, Acadia is a for-profit healthcare company focused on operating inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services in the United States, United Kingdom (“U.K.”) and Puerto Rico.

The Class Period commences on February 23, 2017, when Acadia issued a release entitled “Acadia Healthcare Reports Fourth Quarter GAAP EPS of $0.48 and Adjusted EPS of $0.59; Establishes Financial Guidance for 2017.” On February 24, 2017, Acadia filed with the SEC its annual report on Form 10-K for the year ended December 31, 2016. The 2016 Form 10-K discussed the “[f]avorable industry and legislative trends” that Acadia believed were one of its “competitive strengths,” specifically including its U.K. operations. The 2016 Form 10-K, also characterized Acadia as “the leading independent provider of mental health services in the U.K.”

The complaint alleges that, on October 24, 2017, Acadia issued a release announcing its financial results for the third quarter of 2017. Contrary to the defendants’ representations, Acadia revealed a drastic shortfall in EBITDA for its U.K. operations, purportedly resulting from “lower census and higher operating costs.” In addition, Acadia lowered its financial guidance for 2017, including lowering its EPS guidance by as much as $0.24 per share.

Following this news, Acadia stock lost 26% of its value, falling from a closing price of $44.12 per share on October 24, 2017 to a closing price of $32.68 per share on October 25, 2017.

The complaint alleges that throughout the Class Period, the defendants misrepresented and failed to disclose that: (a) the quality of Acadia’s U.K. operations did not give Acadia a “competitive strength” that would drive future growth and profitability; and (b) the defendants had no reasonable basis to believe and did not in fact believe their positive statements about the company’s business and financial prospects during the Class Period, including their guidance issued and reaffirmed throughout the Class Period.

If you are a member of the class described above, you may no later than December 3, 2018 move the Court to serve as lead plaintiff of the class, if you so choose.

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of their choice, or may choose to do nothing and remain an inactive class member.

Kessler Topaz Meltzer & Check, LLP has not filed a complaint in this matter.  If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
1-888-299-7706 (toll free) or 1-610-667-7706
Or by e-mail at

Please complete this form relating to your transactions for Acadia Healthcare Company, Inc. (Nasdaq: ACHC) securities between February 23, 2017 and October 24, 2017, inclusive (the “Class Period”).

Once completed, please click the orange “Submit Your Information” button at the bottom of this page. You may also contact James Maro, Jr., Esq. or Adrienne Bell, Esq. at 610.667.7706 or toll free at 888.299.7706, or you may submit your information via email at

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Acadia Healthcare Company, Inc. prior to the Class Period?
Are you a current or former employee of Acadia Healthcare Company, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC
I would like to receive
new case alerts by email